Well, its taken me a year longer than I expected. I’m starting back in December 2017 — I need ideas on companies to value. Suggestions welcome!
Update Oct 2019: Well, fuccck! I’m still not there yet. Time is passing me by.
Well, its taken me a year longer than I expected. I’m starting back in December 2017 — I need ideas on companies to value. Suggestions welcome!
Update Oct 2019: Well, fuccck! I’m still not there yet. Time is passing me by.
Yours truly has a new job after fifteen years in the exact same position. I’m moving from entirely a technical position to a technical/sales mix type of position.
Since this is something relatively new to me, I’ve decided to take some time off of my biotech valuation interest to spend it on my new career. I’m sure when things settle down a bit, I’ll be back at biotech valuations. Wish me luck — I’m hoping to be back by the end of this year!
You know you’ve made it when others value your time more than you do.
How do I even come up with this stuff? Someone, please give me a company to value. lol.
Two words when combined together irks the crap outta me.
Unless you’re sitting in a hospital bed immobilized somehow, I don’t even see this as something possible.
I mean, we’re all on borrowed time. There’s always things to do, people to see, places to be — and it could be your own damn couch watching TV, relaxing. Time is passing you by, you’re not passing time.
Or maybe these folks are immortal, what do I know?
Or maybe instead of writing passing time, they should just write relaxing to not piss me off. lol.
Somewhere there’s a reason why things don’t go my way.
Somewhere there’s a reason that I cannot explain.
Just like the change of season just may not be my turn.
But I know there’s a reason the lesson’s mine to learn.
Maybe I don’t like it, but I have no choice
I know that somewhere, someone hears my voice
I hearby declare Mr. Mustaine the best poet that ever lived. No doubt.
Some folks define themselves by the work they do. Some define themselves with their money, celebrity status, whatever.
I’m usually most troubled by people who define their lives based on the work they do, but that’s just me. I can’t seem to do that — Its only a job to me.
At the end of the day, who am I? Does that mean I’m a lost soul with no purpose? Maybe — but then does it even matter?
Philosophical this morning. I must be hungry!
Talking about hungry, I love my omelette dude — one man army of the eggvolution. He sells these omelettes with all sortsa veggies and meats for $2.66. Best. Value. Ever. Now only if biotech stocks were this easy!
Wait, does this define me as soldier #2 for the eggvolution? I need to eat. Forget this.
Analysis on Neuralstem.
I’m very conflicted on this equity. Whether to trust my value, or to realize that its price is close to its 52 week low and the only way looks to be up.
Value vs. Price — ain’t that the conundrum?
Neuralstem March 28, 2016
I’m not sick. But I don’t feel a 100%.
And I can’t concentrate at all.
Yeah, its been that kinda day already. Gardenbitch.com state of being sucks!
Thanks Larry for the wordplay!
Update 3/8:
Well, I’m not sick part went outta the door very quickly. This friggin weekend all I did was sleep, eat cookies and tell my wife that nobody loved me (isn’t that what everyone does when they’re sick?). lol.
On that topic, apparently now you can get antivirals for a common flu. I don’t get it. Says the guy who talks about biotech investing. Do as I say..not..what?
4/20/16:
Last few weeks have been quite challenging and haven’t had a chance to work on any valuation at all. Plan is to get back on track the week of 4/25.
3/28/16:
CUR uploaded. CUR
Now to find something else. I’m too lazy to go back to CLBS — I think.
I’ve also figured out that it takes me around 60 hours per report. Working on it 2 hours a day makes it 10 hours a week. It realistically takes me about 6 weeks to finish a report. Dang, there goes my weekends.
CUR preliminary analysis is about $0.63. I’ll have to do a more through analysis, but not looking like it’ll change a whole lot.
As of Feb 30,2016: CUR
and then maybe CLBS.
Leave comments here, if there’s a stem cell company you’re interested in that you’d like my analysis on. I can’t guarantee when/how/ or if it’ll be done. But rest assured, I will try to get it done.
Just as a quick exercise research, an initial value opinion was set at $1.07 in Mid December,2015. The value was based solely on Metastatic Melanoma data. Since then, the stock has lost quite a bit of ground. Perhaps a candidate for a closer look again.